In conclusion, a higher level of HER2 amplification by ISH was associated with a longer PFS and OS in HER2-positive advanced breast cancer patients treated with first-line pertuzumab, trastuzumab, and docetaxel. Here, ERBB2 is linked to breast carcinoma.